Aromatase Inhibition Therapy
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anatomic Stage I Breast Cancer AJCC v8
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Trial Timeline
Dec 12, 2024 → Dec 31, 2027
NCT ID
NCT06534125About Aromatase Inhibition Therapy
Aromatase Inhibition Therapy is a pre-clinical stage product being developed by Bristol Myers Squibb for Anatomic Stage I Breast Cancer AJCC v8. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06534125. Target conditions include Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06534125 | Pre-clinical | Recruiting |
Competing Products
13 competing products in Anatomic Stage I Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 33 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 49 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 25 |
| Neratinib | Puma Biotechnology | Phase 2 | 44 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |